Anti-cytokine therapy in systemic lupus erythematosus
Anti-cytokine therapy in systemic lupus erythematosus
复制标题
DOI：
10.1191/0961203305lu2134oa
复制
发表时间：
2005-01-01
期刊：
影响因子：
2.6
通讯作者：
Aringer, M
中科院分区：
文献类型：
--
作者：
Smolen, JS;Steiner, G;Aringer, M
In the course of the disease, a wide variety of cytokines is dysregulated, many of which likely influence systemic lupus erythematosus (SLE) autoimmunity and/or lupus tissue inflammation. Proinflammatory cytokines in particular, such as TNF, IL-6, IL-18 or IFN-gamma, may play a major role in propagating the inflammatory processes responsible for tissue damage. These cytokines are overexpressed both systemically and locally, and preliminary results from open-label trials and/or animal studies suggest potential benefits of blocking either of these inflammatory mediators. Since new therapeutic agents may soon offer many ways to influence the process, controlled clinical trials following open-label safety studies are of central importance to arrive at optimized therapies for SLE patients.
